Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled cenerimod mass balance and pharmacokinetics study in healthy men
NL-OMON42951Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cenerimod in systemic lupus erythematosus (SLE) and autoimmune disease, sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change from baseline in vital signs, Change from baseline in ECG variables and 9 more. Started Sep 2016; status: active, not recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)autoimmune disease
Beyond the preview
Go deeper on NL-OMON42951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42951.